<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01614041</url>
  </required_header>
  <id_info>
    <org_study_id>DSPC-SED-1101</org_study_id>
    <nct_id>NCT01614041</nct_id>
  </id_info>
  <brief_title>Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder</brief_title>
  <acronym>TACGAD</acronym>
  <official_title>Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder: a Multi-center, Randomized, Usual Dose-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Pharmaceutical (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Pharmaceutical (Suzhou) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of comparative high dose
      Tandospirone Citrate in the treatment of patients with generalized anxiety disorder.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Anxiety Scale (HAMA) score changes from baseline to 6 weeks treatment</measure>
    <time_frame>6 weeks</time_frame>
    <description>Scores 14-21 indicate mild anxiety; scores 21-29 indicate moderate anxiety; scores over 29 indicate severe anxiety</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HAMA factor score changes after treatment</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Generalized Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient randomized to control group is administrated with usual dose of tandospirone treatment, 30 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Comparative high dose of tandospirone treatment, 60 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Usual dose treatment of Tandospirone</intervention_name>
    <description>Usual dose treatment of Tandospirone, oral, 30 mg/day</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparative high dose of tandospirone treatment</intervention_name>
    <description>Comparative high dose of tandospirone treatment, oral, 60 mg/day</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 years old

          -  Male or female

          -  Diagnosed with GAD according to DSM-IV

          -  HAMA score≥17

          -  Provide with written informed consent

          -  Agree to be washed-out for two weeks if receiving SSRI, SNRI or NASA.

        Exclusion Criteria:

          -  Serious suicidal tendency

          -  The score of the sixth item of HAMA ≥3

          -  The score of HAMD ≥21

          -  Pregnant or lactating women

          -  History of allergic or hypersensitivity to tandospirone

          -  Serious or unstable cardiac, renal, neurologic, cerebrovascular, metabolic, or
             pulmonary disease

          -  Secondary anxiety disorders

          -  Drug or alcohol dependence within 1 year

          -  Patients currently taking benzodiazepine drugs

          -  Drivers and dangerous machine operators

          -  Participated in other clinical studies in the last 30 days

          -  Patients with clinically significant ECG or laboratory abnormalities

          -  Patients with a history of epilepsy

          -  Patients with abnormal TSH concentration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenyuan Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Tongji Hospital, Tongji University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenyuan Wu, MD</last_name>
    <phone>86-21-66111487</phone>
    <email>Wuwy@tongji.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Tongji Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200065</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenyuan Wu, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2011</study_first_submitted>
  <study_first_submitted_qc>June 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2012</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Generalized Anxiety Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Tandospirone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

